Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research (Q36840610)

16 August 2017

1 reference

title

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research (English)

1 reference

16 August 2017

0 references

1 reference

Arranz MJ

1

1 reference

16 August 2017

de Leon J

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

5 June 2007

1 reference

16 August 2017

number of pages

41

1 reference

inferred from page(s)

published in

Molecular Psychiatry

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

707-747

1 reference

Cytochrome P4502D6 genotype does not determine response to clozapine

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

Assessing the generalizability of prognostic information

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

Investigation of the phenylalanine hydroxylase gene and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine partial agonists: a new class of antipsychotic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Spotlight on amisulpride in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Duration of untreated psychosis predicts treatment outcome in an early psychosis program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Causes and consequences of duration of untreated psychosis in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Economic issues in access to medications: schizophrenia treatment in England.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clinical pharmacogenomics: applications in pharmaceutical R&D

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenomics of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Twin study of symptom dimensions in psychoses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Heritability estimates for psychotic disorders: the Maudsley twin psychosis series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic basis of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Neuroleptic responsiveness in siblings concordant for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Monozygotic twins concordant for response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clozapine-induced concordant agranulocytosis in monozygotic twins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Familial occurrence of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Olanzapine: concordant response in monozygotic twins with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Difficulties in replication of results

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Application of pharmacogenetics to psychotic disorders: the first consensus conference. The Consensus Group for Outcome Measures in Psychoses for Pharmacological Studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The evolution of drug metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Metabolic drug interactions with new psychotropic agents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The dosing of atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Metabolic drug interactions with newer antipsychotics: a comparative review.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

1 reference

7 January 2021

Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Glucuronidation enzymes, genes and psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacokinetics of clozapine and its metabolites in hippocampal HT22 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Haloperidol half-life after chronic dosing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Cytochrome P450 polymorphisms and response to antipsychotic therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Drug metabolism and atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacokinetics of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Influence of pharmacogenetics on drug disposition and response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Risperidone plasma levels, clinical response and side-effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Smoking impact on CYP1A2 activity in a group of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic basis of toxic reactions to drugs and chemicals.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Atypical antipsychotic dosing: the effect of smoking and caffeine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Identification of a naturally occurring 21 bp deletion in alpha 2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

DRD3 and DAT1 genes in schizophrenia: an association study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clinical applications of pharmacogenetics in psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Antipsychotics and dopamine transporter gene polymorphisms in delirium patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between clozapine response and allelic variation in 5-HT2A receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic variation of the 5-HT2A receptor and response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic variation of 5-HT2A receptor and response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetic prediction of clozapine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The serotonin transporter and clozapine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

An association study of a brain-derived neurotrophic factor Val66Met polymorphism and clozapine response of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of treatment-resistant schizophrenia with the G2677A/T and C3435T polymorphisms in the ATP-binding cassette subfamily B member 1 gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between the methylenetetrahydrofolate reductase 677C-->T missense mutation and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Neuregulin genotype and medication response in Finnish patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

An association study of the neurotensin receptor gene with schizophrenia and clozapine response.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

RGS4 genotype is not associated with antipsychotic medication response in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

No association of tumor necrosis factor alpha gene polymorphisms with schizophrenia or response to clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine transporter genotype and methylphenidate dose response in children with ADHD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Abnormal expression of serotonin transporter mRNA in the frontal and temporal cortex of schizophrenics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Bipolar depression: pharmacotherapy and related therapeutic strategies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

New antipsychotics and schizophrenia: a review on efficacy and side effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Glutamate receptor expression in schizophrenic brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Schizophrenia and glutamatergic transmission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The GABA-glutamate connection in schizophrenia: which is the proximate cause?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Gene expression studies of mRNAs encoding the NMDA receptor subunits NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C, and NMDAR2D following long-term treatment with cis-and trans-flupenthixol as a model for understanding the mode of action of schizophrenia drug t

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association analysis of the genetic variants of the N-methyl D-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Chronic antipsychotics treatment regulates MAOA, MAOB and COMT gene expression in rat frontal cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Neuregulin 1 and susceptibility to schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of neuregulin 1 with schizophrenia confirmed in a Scottish population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A new simple diagnostic assay for the identification of the major CYP2D6 genotypes by DNA sequencing analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics and drug development: the path to safer and more effective drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics of clozapine response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Global variation in copy number in the human genome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene ⋆

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D3 receptor variant and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Tag/anti-tag liquid-phase primer extension array: a flexible and versatile genotyping platform

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphism of the adrenergic receptor alpha 2a -1291C>G genetic variation and clozapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic variants of the serotonin system and weight change during clozapine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D(2) receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

NQO2 gene is associated with clozapine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Implications of the CATIE trial on treatment: extrapyramidal symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Neuroleptic Malignant Syndrome and Atypical Antipsychotic Drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

A haplotype map of the human genome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The effect of single-nucleotide polymorphism marker selection on patterns of haplotype blocks and haplotype frequency estimates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The HapMap project and its application to genetic studies of drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Novel and alternate SNP and genetic technologies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Large-scale genotyping of complex DNA.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

MALDI-TOF mass spectrometry-based SNP genotyping

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Statistical significance for genomewide studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Algorithms for large-scale genotyping microarrays

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Antipsychotic drug treatment induces differential gene expression in the rat cortex.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Using a DNA microarray method to examine gene expression in brain from clozapine-injected mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Impact of haloperidol and risperidone on gene expression profile in the rat cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

cDNA array reveals increased expression of glucose-dependent insulinotropic polypeptide following chronic clozapine treatment: role in atypical antipsychotic drug-induced adverse metabolic effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The draft sequences. Comparing species.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

1 reference

7 January 2021

Epigenetics and twins: three variations on the theme.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Genetics and Epigenetics in Major Psychiatric Disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Evidence that RNA editing modulates splice site selection in the 5-HT2C receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Phosphorylation of ERK and CREB in cultured hippocampal neurons after haloperidol and risperidone administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002009

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4002009

1 reference

Dimensions Publication ID

16 August 2017

1042780954

0 references

1 reference